Per Munck Af Rosenschold1, Junia Costa1, Svend Aage Engelholm1, Michael J Lundemann1, Ian Law1, Lars Ohlhues1, Silke Engelholm1. 1. Department of Oncology, Section of Radiotherapy, Rigshospitalet, Copenhagen, Denmark (P.M.a.R., J.C., S.A.E., M.J.L., L.O.); Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark (P.M.a.R., M.J.L.); Department of Clinical Physiology, Nuclear Medicine, and PET, Rigshospitalet, Copenhagen, Denmark (I.L., J.C.); Section of Radiation Oncology, Skåne University Hospital, Lund, Sweden (S.E.).
Abstract
BACKGROUND: We sought to assess the impact of amino-acid (18)F-fluoro-ethyl-tyrosine (FET) positron emission tomography (PET) on the volumetric target definition for radiation therapy of high-grade glioma versus the current standard using MRI alone. Specifically, we investigated the influence of tumor grade, MR-defined tumor volume, and the extent of surgical resection on PET positivity. METHODS: Fifty-four consecutive high-grade glioma patients (World Health Organization grades III-IV) with confirmed histology were scanned using FET-PET/CT and T1 and T2/fluid attenuated inversion recovery MRI. Gross tumor volume and clinical target volumes (CTVs) were defined in a blinded fashion based on MRI and subsequently PET, and volumetric analysis was performed. The extent of the surgical resection was reviewed using postoperative MRI. RESULTS: Overall, for ∼ 90% of the patients, the PET-positive volumes were encompassed by T1 MRI with contrast-defined tumor plus a 20-mm margin. The tumor volume defined by PET was larger for glioma grade IV (P < .001) and smaller for patients with more extensive surgical resection (P = .004). The margin required to be added to the MRI-defined tumor in order to fully encompass the FET-PET positive volume tended to be larger for grade IV tumors (P = .018). CONCLUSION: With an unchanged CTV margin and by including FET-PET for gross tumor volume definition, the CTV will increase moderately for most patients, and quite substantially for a minority of patients. Patients with grade IV glioma were found to be the primary candidates for PET-guided radiation therapy planning.
BACKGROUND: We sought to assess the impact of amino-acid (18)F-fluoro-ethyl-tyrosine (FET) positron emission tomography (PET) on the volumetric target definition for radiation therapy of high-grade glioma versus the current standard using MRI alone. Specifically, we investigated the influence of tumor grade, MR-defined tumor volume, and the extent of surgical resection on PET positivity. METHODS: Fifty-four consecutive high-grade gliomapatients (World Health Organization grades III-IV) with confirmed histology were scanned using FET-PET/CT and T1 and T2/fluid attenuated inversion recovery MRI. Gross tumor volume and clinical target volumes (CTVs) were defined in a blinded fashion based on MRI and subsequently PET, and volumetric analysis was performed. The extent of the surgical resection was reviewed using postoperative MRI. RESULTS: Overall, for ∼ 90% of the patients, the PET-positive volumes were encompassed by T1 MRI with contrast-defined tumor plus a 20-mm margin. The tumor volume defined by PET was larger for glioma grade IV (P < .001) and smaller for patients with more extensive surgical resection (P = .004). The margin required to be added to the MRI-defined tumor in order to fully encompass the FET-PET positive volume tended to be larger for grade IV tumors (P = .018). CONCLUSION: With an unchanged CTV margin and by including FET-PET for gross tumor volume definition, the CTV will increase moderately for most patients, and quite substantially for a minority of patients. Patients with grade IV glioma were found to be the primary candidates for PET-guided radiation therapy planning.
Authors: Yaacov Richard Lawrence; X Allen Li; Issam el Naqa; Carol A Hahn; Lawrence B Marks; Thomas E Merchant; Adam P Dicker Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Benoit J M Pirotte; Alphonse Lubansu; Nicolas Massager; David Wikler; Patrick Van Bogaert; Marc Levivier; Jacques Brotchi; Serge Goldman Journal: J Neurosurg Pediatr Date: 2010-05 Impact factor: 2.375
Authors: M Bergström; V P Collins; E Ehrin; K Ericson; L Eriksson; T Greitz; C Halldin; H von Holst; B Långström; A Lilja Journal: J Comput Assist Tomogr Date: 1983-12 Impact factor: 1.826
Authors: Michael T Milano; Paul Okunieff; Rosemary S Donatello; Nimish A Mohile; Joohee Sul; Kevin A Walter; David N Korones Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-06 Impact factor: 7.038
Authors: Frederic G Dhermain; Peter Hau; Heinrich Lanfermann; Andreas H Jacobs; Martin J van den Bent Journal: Lancet Neurol Date: 2010-08-10 Impact factor: 44.182
Authors: Karl-Josef Langen; Michael Jarosch; Heinz Mühlensiepen; Kurt Hamacher; Stefan Bröer; Paul Jansen; Karl Zilles; Heinz H Coenen Journal: Nucl Med Biol Date: 2003-07 Impact factor: 2.408
Authors: Damien C Weber; Nathalie Casanova; Thomas Zilli; Franz Buchegger; Michel Rouzaud; Philippe Nouet; Hansjorg Vees; Osman Ratib; Giovanna Dipasquale; Raymond Miralbell Journal: Radiother Oncol Date: 2009-09-24 Impact factor: 6.280
Authors: Luis Souhami; Wendy Seiferheld; David Brachman; Ervin B Podgorsak; Maria Werner-Wasik; Robert Lustig; Christopher J Schultz; William Sause; Paul Okunieff; Jan Buckner; Lucia Zamorano; Minesh P Mehta; Walter J Curran Journal: Int J Radiat Oncol Biol Phys Date: 2004-11-01 Impact factor: 7.038
Authors: Damien C Weber; Thomas Zilli; Franz Buchegger; Nathalie Casanova; Guy Haller; Michel Rouzaud; Philippe Nouet; Giovanna Dipasquale; Osman Ratib; Habib Zaidi; Hansjorg Vees; Raymond Miralbell Journal: Radiat Oncol Date: 2008-12-24 Impact factor: 3.481
Authors: Robert H Press; Jim Zhong; Saumya S Gurbani; Brent D Weinberg; Bree R Eaton; Hyunsuk Shim; Hui-Kuo G Shu Journal: Neurosurgery Date: 2019-08-01 Impact factor: 4.654
Authors: Norbert Galldiks; Karl-Josef Langen; Nathalie L Albert; Marc Chamberlain; Riccardo Soffietti; Michelle M Kim; Ian Law; Emilie Le Rhun; Susan Chang; Julian Schwarting; Stephanie E Combs; Matthias Preusser; Peter Forsyth; Whitney Pope; Michael Weller; Jörg C Tonn Journal: Neuro Oncol Date: 2019-05-06 Impact factor: 12.300
Authors: Mikael Agn; Per Munck Af Rosenschöld; Oula Puonti; Michael J Lundemann; Laura Mancini; Anastasia Papadaki; Steffi Thust; John Ashburner; Ian Law; Koen Van Leemput Journal: Med Image Anal Date: 2019-03-22 Impact factor: 8.545
Authors: Norbert Galldiks; Maximilian Niyazi; Anca L Grosu; Martin Kocher; Karl-Josef Langen; Ian Law; Giuseppe Minniti; Michelle M Kim; Christina Tsien; Frederic Dhermain; Riccardo Soffietti; Minesh P Mehta; Michael Weller; Jörg-Christian Tonn Journal: Neuro Oncol Date: 2021-06-01 Impact factor: 12.300
Authors: Oliver Oehlke; Michael Mix; Erika Graf; Tanja Schimek-Jasch; Ursula Nestle; Irina Götz; Sabine Schneider-Fuchs; Astrid Weyerbrock; Irina Mader; Brigitta G Baumert; Susan C Short; Philipp T Meyer; Wolfgang A Weber; Anca-Ligia Grosu Journal: BMC Cancer Date: 2016-10-05 Impact factor: 4.430